RxDoctor Payments Data

Thomas Cimato

Cardiovascular Disease · Amherst, NYNPI 1497942809

Payments from drug & device makers

$204,230in general payments, 2019–2025

Across 60 payments — averaging $3403.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$158K
  • Edwards Lifesciences$32K
  • AstraZeneca$12K
  • Impulse Dynamics (USA) Inc.$765
  • Boston Scientific$172
  • Abiomed$125
  • plus $344 from 7 others

What the payments were for

  • Food & beverage$889100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$204,230 in reported general payments places this provider in the 95th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$110,981
Medicare patients
323
Services billed
1,174

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis12$311,444
EliquisApixaban164$215,517
EntrestoSacubitril/Valsartan134$153,583
XareltoRivaroxaban53$87,789
JardianceEmpagliflozin74$79,552
FarxigaDapagliflozin Propanediol46$60,427
Repatha SureclickEvolocumab48$27,112
BrilintaTicagrelor24$20,401
Bumetanide202$8,726
Metoprolol Succinate453$8,141
Dabigatran EtexilateDabigatran Etexilate Mesylate12$7,009
Rosuvastatin Calcium320$5,252
Isosorbide Dinitrate26$4,994
Atorvastatin Calcium271$3,729
Carvedilol198$2,554

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$158,458$153,583134 claims
AstraZenecaFarxiga, Brilinta$11,872$80,82970 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Amherst

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →